Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects. - Ruocco, MG; Pilones, K; Kawashima, N; Cammer, M; Huang, J; Babb, J; Liu, M; Formenti, S; Dustin, M; Demaria, S (Journal of clinical investigation, 2012)